SINOVAC Announces New Board Member and Chairman of the Audit Committee
Sinovac Biotech (NASDAQ:SVA) has appointed Sven H. Borho, CFA, as a new director to its Board of Directors and Chairman of the Audit Committee. Borho, a founder and Managing Partner of OrbiMed, brings over 30 years of healthcare investment experience to the role.
OrbiMed, a leading healthcare investment firm managing approximately $17 billion in assets, has been a SINOVAC shareholder since 2013 and currently holds over 2.7 million shares. The firm invests globally across the healthcare industry through various funds.
Following this appointment, SINOVAC's Board now comprises five members: Dr. Chiang Li (Chairman), Mr. Yuk Lam Lo, Dr. David Guowei Wang, Mr. Pengfei Li, and Mr. Sven H. Borho. The Audit Committee consists of Borho, Lo, and Wang.
Sinovac Biotech (NASDAQ:SVA) ha nominato Sven H. Borho, CFA come nuovo direttore del Consiglio di Amministrazione e Presidente del Comitato di Controllo. Borho, fondatore e Managing Partner di OrbiMed, porta oltre 30 anni di esperienza negli investimenti nel settore sanitario nel suo nuovo ruolo.
OrbiMed, una delle principali società di investimento nel settore sanitario con circa 17 miliardi di dollari in gestione, è azionista di SINOVAC dal 2013 e attualmente detiene oltre 2,7 milioni di azioni. La società investe a livello globale nel settore sanitario attraverso vari fondi.
Dopo questa nomina, il Consiglio di SINOVAC è composto da cinque membri: Dr. Chiang Li (Presidente), Mr. Yuk Lam Lo, Dr. David Guowei Wang, Mr. Pengfei Li e Mr. Sven H. Borho. Il Comitato di Controllo è costituito da Borho, Lo e Wang.
Sinovac Biotech (NASDAQ:SVA) ha nombrado a Sven H. Borho, CFA como nuevo director de su Junta Directiva y Presidente del Comité de Auditoría. Borho, fundador y Socio Director de OrbiMed, aporta más de 30 años de experiencia en inversiones en el sector salud a este cargo.
OrbiMed, una destacada firma de inversión en salud que gestiona aproximadamente 17 mil millones de dólares en activos, ha sido accionista de SINOVAC desde 2013 y actualmente posee más de 2,7 millones de acciones. La firma invierte a nivel global en la industria de la salud a través de varios fondos.
Tras esta designación, la Junta de SINOVAC ahora está compuesta por cinco miembros: Dr. Chiang Li (Presidente), Mr. Yuk Lam Lo, Dr. David Guowei Wang, Mr. Pengfei Li y Mr. Sven H. Borho. El Comité de Auditoría está formado por Borho, Lo y Wang.
시노백 생명공학 (NASDAQ:SVA)는 스벤 H. 보르호, CFA를 이사회의 새로운 이사이자 감사위원회 의장으로 임명했습니다. 보르호는 오르비메드의 창립자이자 관리 파트너로서 30년 이상의 헬스케어 투자 경험을 이 역할에 가져옵니다.
오르비메드는 약 170억 달러의 자산을 관리하는 선도적인 헬스케어 투자 회사로, 2013년부터 SINOVAC의 주주이며 현재 270만 주 이상의 주식을 보유하고 있습니다. 이 회사는 다양한 기금을 통해 헬스케어 산업에 전 세계적으로 투자합니다.
이번 임명 이후, SINOVAC의 이사회는 다섯 명의 구성원으로 이루어져 있습니다: Dr. Chiang Li (의장), Mr. Yuk Lam Lo, Dr. David Guowei Wang, Mr. Pengfei Li 및 Mr. Sven H. Borho. 감사위원회는 보르호, 로, 왕으로 구성됩니다.
Sinovac Biotech (NASDAQ:SVA) a nommé Sven H. Borho, CFA comme nouveau directeur de son Conseil d'Administration et Président du Comité d'Audit. Borho, fondateur et Associé Gérant de OrbiMed, apporte plus de 30 ans d'expérience en investissement dans le secteur de la santé à ce poste.
OrbiMed, une société d'investissement leader dans le secteur de la santé gérant environ 17 milliards de dollars d'actifs, est actionnaire de SINOVAC depuis 2013 et détient actuellement plus de 2,7 millions d'actions. La société investit à l'échelle mondiale dans l'industrie de la santé à travers divers fonds.
Suite à cette nomination, le Conseil de SINOVAC se compose désormais de cinq membres : Dr. Chiang Li (Président), Mr. Yuk Lam Lo, Dr. David Guowei Wang, Mr. Pengfei Li et Mr. Sven H. Borho. Le Comité d'Audit est composé de Borho, Lo et Wang.
Sinovac Biotech (NASDAQ:SVA) hat Sven H. Borho, CFA als neuen Direktor in den Vorstand und als Vorsitzenden des Prüfungsausschusses berufen. Borho, Gründer und geschäftsführender Partner von OrbiMed, bringt über 30 Jahre Erfahrung im Bereich Gesundheitsinvestitionen in diese Rolle ein.
OrbiMed, eine führende Investmentgesellschaft im Gesundheitswesen mit einem verwalteten Vermögen von etwa 17 Milliarden Dollar, ist seit 2013 Aktionär von SINOVAC und hält derzeit über 2,7 Millionen Aktien. Das Unternehmen investiert global in die Gesundheitsbranche über verschiedene Fonds.
Nach dieser Ernennung besteht der Vorstand von SINOVAC nun aus fünf Mitgliedern: Dr. Chiang Li (Vorsitzender), Mr. Yuk Lam Lo, Dr. David Guowei Wang, Mr. Pengfei Li und Mr. Sven H. Borho. Der Prüfungsausschuss besteht aus Borho, Lo und Wang.
- Appointment of experienced financial expert (30+ years) to Board and Audit Committee
- Strong institutional backing with OrbiMed (managing $17B) holding significant stake
- Maintains full Board composition with 5 members
- Recent director resignation creating the vacancy
Mr. Borho is a founder and Managing Partner of OrbiMed and has over 30 years of experience investing in the healthcare sector. OrbiMed is a leading healthcare investment firm with approximately
Following this appointment, the Board consists of five members, including Dr. Chiang Li (Chairman), Mr. Yuk Lam Lo, Dr. David Guowei Wang, Mr. Pengfei Li, and Mr. Sven H. Borho, CFA. The Audit Committee of the Board consists of three members, including Mr. Borho, Mr. Lo and Dr. Wang. Dr. Li, Mr. Lo and Dr. Wang remain members of the Compensation Committee and the Corporate Governance and Nominating Committee.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a
SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please visit the Company’s website at www.sinovac.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327445606/en/
Sinovac Biotech Ltd.
Helen Yang
Tel: +86-10-8279 9779
Email: ir@sinovac.com
Source: Sinovac Biotech Ltd.
FAQ
Who is the new Board member appointed to Sinovac Biotech (SVA)?
How many shares does OrbiMed currently hold in Sinovac (SVA)?
How long has OrbiMed been a shareholder of Sinovac (SVA)?
What is the current composition of Sinovac's (SVA) Board of Directors?
